Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | CAMK2A | Q9UQM7 | 3/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29899638 | 1.00 | GRIK1 (0.46) | GRIK1CAMK2AAKR1B1CA2PYCR1 | |
| SCHEMBL154416 | 0.85 | PTGDR2 (0.44) | GRIK1CAMK2AAKR1B1CA2CXCL8 | |
| SCHEMBL1350652 | 0.83 | PYCR1 (0.44) | PYCR1MGAMGAASIMGAM2 | |
| SCHEMBL2951923 | 0.83 | PYCR1 (0.41) | PYCR1DGAT1MGAMGAASI | |
| SCHEMBL20567700 | 0.81 | SRC (0.59) | CAMK2AAKR1B1CA2CXCL8DGAT1 | |
| SCHEMBL30917833 | 0.80 | F13A1 (0.44) | — | |
| SCHEMBL260512 | 0.80 | CHRM1 (0.57) | CXCL8 | |
| SCHEMBL10479066 | 0.80 | PTGDR2 (0.42) | GRIK1AKR1B1PYCR1PTGDR2 | |
| SCHEMBL6456130 | 0.80 | AKR1B1 (0.52) | GRIK1CAMK2AAKR1B1GAAPTGDR2 | |
| SCHEMBL29419329 | 0.80 | CHRM1 (0.57) | CXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101208347-B | Method of preparing clopidogrel and intermediates used therein | HANMI PHARM IND CO LTD | 2011-01-12 | — | — | CN | claimed |
| CN-101208347-A | Method of preparing clopidogrel and intermediates used therein | HANMI PHARM IND CO LTD (KR) | 2008-06-25 | — | — | CN | claimed |
| CN-100390180-C | Clopidogrel and its salt preparing method | SHANGHAI APPLIED TECHNOLOGY CO (CN) | 2008-05-28 | — | — | CN | claimed |
| CN-1775782-A | Clopidogrel and its salt preparing method | SHANGHAI APPLIED TECHNOLOGY CO (CN) | 2006-05-24 | — | — | CN | claimed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025006553-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024067560-A1 | SULFONAMIDE COMPOUND AND MEDICAL USE THEREOF | 中国药科大学 | 2024-04-04 | — | — | WO | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| WO-2024039901-A2 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024009232-A1 | SUBSTITUTED N-(PYRIDIN-2-YL)ACETAMIDE DERIVATIVES AS CDK12/13 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-01-11 | — | — | WO | disclosed |
| CN-1775782-A | Clopidogrel and its salt preparing method | SHANGHAI APPLIED TECHNOLOGY CO (CN) | 2006-05-24 | — | — | CN | disclosed |
| US-20050288318-A1 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2005-12-29 | — | — | US | disclosed |
| EP-1556382-A1 | 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041817-A1 | 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2004-05-21 | — | — | WO | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| CN-1292697-A | Anti-viral compound | LILLY CO ELI (US) | 2001-04-25 | — | — | CN | disclosed |
| EP-1077701-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | GRIK1 1887/4885CAMK2A 4033/4885AKR1B1 610/4885 |
| US-20050288318-A1 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | PNPO, PDXK, PLPBP | GRIK1 2801/4885CAMK2A 2986/4885AKR1B1 102/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | GRIK1 1418/4885CAMK2A 1990/4885AKR1B1 2707/4885 |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | GRIK1 3991/4885CAMK2A 787/4885AKR1B1 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.